Logo Logo Logo Logo Logo
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Careers
  • Partnering
  • Contact us
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Careers
  • Partnering
  • Contact us

28 Jul Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases

Posted at 10:00h in News
Share

...

Read More

31 Mar Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances

Posted at 08:00h in News
Share
Read More

10 Mar Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets

Posted at 15:00h in News
Share
Read More

07 Oct Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody™ therapeutics

Posted at 07:00h in News
Share
Read More

19 Sep A new technology for targeting proteins inside cells

Posted at 08:00h in News
Share
Read More

14 Dec Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies™ against intracellular cancer targets

Posted at 09:00h in News
Share
Read More

27 Jul Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies

Posted at 09:00h in News
Share
Read More

06 Jan Complix Enters into Strategic Collaboration with Merck Inc, worth up to US$ 280 million

Posted at 09:00h in News
Share
Read More

14 Dec Complix Advances Novel Bispecific Immunotherapeutic CMX-02 – Enters Agreement with Selexis to Access SUREtechnology Platform™

Posted at 09:00h in News
Share
Read More

28 Oct Complix to Present at CHI’s 7th Annual PEGS Europe Summit, November 5, 2015

Posted at 09:00h in News
Share
Read More
  • 1
  • 2
About Complix
Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics active against cutting-edge and challenging intracellular targets that play a key role in life threatening diseases, including cancer.
Recent news
  • Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases July 28, 2021
  • Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances March 31, 2021
  • Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets March 10, 2021
Complix newsletter
Subscribe to the Complix newsletter & stay up to date with news, events & projects.
Contact us
Technologiepark 94
9052 Zwijnaarde (Ghent)
Belgium
Phone: +32 (0)9 261 69 40
Fax: +32 (0)9 261 69 50
E-Mail: info@complix.com
© 2021 Complix | Terms of use | Privacy policy | Cookie policy